STAT3 and melanoma: In in vivo prospective studies involving patients with a clinical history of resected primary melanoma who had at least four atypical nevi, systemic low dose IFN-α treatment for three months led to decreased detection of Stat3/Stat3 and Stat1/Stat1 homodimers and Stat1/Stat3 heterodimer in atypical nevi excised after completion of treatment compared to those resected before IFN-α treatment.